Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Cidara Therapeutics is a biotechnology company developing drug-Fc conjugate therapeutics, with its lead program CD388 designed to prevent influenza infection in high-risk populations. CD388 advanced into...
— Patrick Kelly, Dan Chung, Ankur Crawford
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Cidara Therapeutics, Inc.
No other institutional pitches found for this ticker yet.